Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss the outlook for healthcare stocks, and the latest news on Covid-19 treatments and vaccines.
Oct 19
How To Invest In AI Now With Janus Henderson’s Jonathan Cofsky
Join Barron's Live for a deep dive into how a technology investor is assessing AI buildout concerns, competition from China and which AI heavyweights, like Nvidia, TSMC, Samsung and SK Hynix, are still undervalued. Associate Editor Reshma Kapadia speaks with Jonathan Cofsky, port ... Show More
50m 18s
Oct 13
Batter Up! Investing in the Sports Boom with Gabelli Funds’ Chris Marangi
Sports is a burgeoning asset class, and there are many ways for public investors to play a winning game. Barron’s Senior Managing Editor Lauren R. Rublin and Associate Editor Andrew Bary speak with Christopher J. Marangi, President & Co-CIO, Value at GAMCO/Gabelli Funds, about in ... Show More
39m 33s
Oct 6
Where Are Markets Headed? A Technical Analyst Sizes Up the Latest Turmoil
Andy Addison, proprietor of The Institutional View newsletter and research service, is a veteran technical analyst. He studies price action, moving averages, relative strength, and momentum indicators to gauge where asset prices may be headed. Barron's Senior Managing Editor Laur ... Show More
41m 55s
Mar 2020
Live from the Compound (from Long Island)
Michael Batnick and Downtown Josh Brown discuss all of the recent market volatility from the COVID-19 situation, including some takes on stock buybacks, what 13Fs might look like, the 10 stocks that have raised their dividends for 50 years straight, the overall damage so far and ... Show More
21m 48s
Nov 2020
COVID-19 Vaccine Optimism, Business Leaders' Message To President Trump, And Retail Stocks' Big November Rally
<p>Kicking off a holiday-shortened week for the markets, Jim Cramer and David Faber highlighted the latest vaccine news to lift stocks: AstraZeneca announced that its COVID-19 vaccine being developed in conjunction with Oxford University was up to 90 percent effective with no ser ... Show More
42m 24s
Apr 2020
Gilead Virus Treatment Is Promising But No Silver Bullet Yet
Sam Fazeli, Director of Research: EMEA for Bloomberg Intelligence, on Gilead's positive trial for a potential coronavirus treatment. Lisa Shalett, Chief Investment Officer: Wealth Management for Morgan Stanley, discusses why she wants clients to avoid S&P indices and to actively ... Show More
30m 3s